TMPRSS6 and Rare hereditary hemochromatosis: The finding of the non-proteolytic function in matriptase-2 suggests that targeting matriptase-2 binding to its substrates may be considered as a new approach to increase hepcidin expression as a therapy for iron overload diseases [101].